ESR1 and neoplasm: Meta-analysis of numerous randomised clinical trials of adjuvant tamoxifen versus no tamoxifen conclusively revealed that patients with tumours with < 10fmol ER/mg protein when measured by LBA/DCC gained no significant reduction in risk of recurrence from tamoxifen treatment [5].